Mahkam Zanganeh - 02 Jan 2026 Form 4 Insider Report for Summit Therapeutics Inc. (SMMT)

Reporting relationship: Co-Chief Executive Officer, Director, 10%+ Owner
Issuer ticker: SMMT
Reported as of: 02 Jan 2026
Net transaction value: +$98,392
SEC form: 4
Accepted by SEC: 06 Jan 2026, 19:52:54 UTC
Prior SEC filing: 23 Oct 2025
Next SEC filing: 04 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Mahkam Zanganeh

Key filing fact

Mahkam Zanganeh filed Form 4 for Summit Therapeutics Inc. (SMMT) on 06 Jan 2026.

Key facts

This page summarizes Mahkam Zanganeh's Form 4 filing for Summit Therapeutics Inc. (SMMT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2026, 19:52.

Change

Previous filing in this sequence was filed on 23 Oct 2025.
Current net transaction value: +$98,392.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001507650 Primary reporting owner

Zanganeh Mahkam

Relationship: Co-Chief Executive Officer, Director, 10%+ Owner
Address: C/O SUMMIT THERAPEUTICS INC., 601 BRICKELL KEY DRIVE, SUITE 1000, MIAMI
Signature: /s/ Mahkam Zanganeh
Signature date: 06 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SMMT transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $98,392
Shares: +11,232
Change %
Price: $8.76
Shares after: 11,232
Date: 02 Jan 2026
Ownership: By Spouse
Underlying class: Common Stock
Underlying amount: 11,232
Exercise price: $17.52
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person's spouse remaining as a non-salaried director on each such vesting date.

Footnote F2

The option was issued to the reporting person's spouse pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $98,400.

Footnote F3

The reporting person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or any other purpose.